Walleye Capital LLC Takes Position in Sionna Therapeutics, Inc. $SION

Walleye Capital LLC bought a new stake in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,097 shares of the company’s stock, valued at approximately $605,000.

Other hedge funds also recently bought and sold shares of the company. Viking Global Investors LP raised its holdings in shares of Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after acquiring an additional 242,427 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Sionna Therapeutics by 30.1% during the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after buying an additional 335,942 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after acquiring an additional 41,797 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Sionna Therapeutics by 30.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock valued at $34,203,000 after acquiring an additional 193,613 shares during the period. Finally, State Street Corp raised its stake in Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after acquiring an additional 453,196 shares during the last quarter.

Insider Buying and Selling

In related news, Director Peter A. Thompson sold 184,639 shares of Sionna Therapeutics stock in a transaction on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the sale, the director owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This trade represents a 6.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. The trade was a 6.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 989,630 shares of company stock worth $44,987,483 in the last quarter. Insiders own 5.10% of the company’s stock.

Sionna Therapeutics Trading Up 3.7%

NASDAQ SION opened at $45.70 on Friday. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -23.68 and a beta of 1.33. Sionna Therapeutics, Inc. has a twelve month low of $16.38 and a twelve month high of $51.56. The stock has a 50-day moving average of $41.04 and a 200 day moving average of $39.79.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Equities analysts predict that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SION. Wedbush began coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target for the company. Citizens Jmp restated a “market outperform” rating and issued a $63.00 price objective on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Stifel Nicolaus lifted their target price on Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, May 18th. BTIG Research reaffirmed a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.